Metastasis involves the dissociation of cancer cells from the primary tumor mass, followed by their navigation through the circulatory system to colonize remote tissues. Existing studies have indicated that circulating tumor cells (CTCs) more effectively give rise to secondary tumors when they traverse the vasculature as clusters rather than as isolated single cells. These clusters demonstrate increased survival rates in the stressful circulatory environment and display a heightened capacity to establish metastatic colonies. However, the molecular underpinnings facilitating cluster formation, particularly in TNBC, have remained elusive given the aggressive loss of classical cell adhesion molecules in these cancers.

Classical adherens junction proteins are typically responsible for mediating cell-to-cell adhesion, stabilizing clusters through robust intercellular connections. The conundrum arises in TNBC, where these proteins are frequently downregulated or absent, prompting the question: how do TNBC cells compensate to sustain cluster integrity? In their meticulous comparative analyses of TNBC versus non-TNBC cells, as well as metastatic versus non-metastatic breast tumors, the research team identified a critical role for components of the extracellular matrix (ECM), with a particular focus on hyaluronan (HA).

The ECM is a highly intricate and dynamic network composed principally of proteins, glycosaminoglycans, and water. It functions as both a structural scaffold and an adhesive substrate, facilitating cellular cohesion and signaling. Hyaluronan, a major glycosaminoglycan in the ECM, emerged from this comparative study as a key player in mediating TNBC cell clustering. This polysaccharide accumulates as a dense, sticky coat on the surface of TNBC cells due to the upregulated activity of hyaluronan synthase 2 (HAS2), an enzyme markedly overexpressed in these aggressive cancer cells.

Experimental investigations utilizing mouse metastasis models and patient-derived samples revealed that the HA coat is indispensable for cluster formation. Enzymatic removal of HA from CTCs resulted in the disintegration of previously stable clusters. Furthermore, the cell surface glycoprotein CD44 was identified as a necessary partner, required for the proper presentation of hyaluronan on the cellular membrane. Abrogation of CD44 expression compromised HA localization and consequently inhibited the ability of TNBC cells to aggregate into protective clusters.

The HA-CD44 interaction sets the stage for further stabilization through desmosomal adhesion complexes, which confer mechanical resilience essential for enduring the hemodynamic forces encountered within the bloodstream. These desmosomes reinforce the cluster architecture, enabling the cancer cell conglomerates to resist shear stress-induced damage during circulatory transit. This mechanistic cascade grants TNBC clusters a formidable advantage in surviving the hostile circulatory milieu and enhances their metastatic potential.

Strikingly, the study revealed that HA-mediated clustering confers flexibility absent in the classical adherens junction-mediated clusters. Unlike rigid cell-cell junctions, the HA-based clusters demonstrate a pliability that permits transient disassembly when navigating the narrow capillary networks. Cells temporarily elongate into single-file arrangements while maintaining contact, subsequently reassembling into cohesive clusters post-capillary transit. This dynamic behavior provides a critical survival mechanism that maximizes metastatic efficiency without sacrificing cluster integrity.

Beyond physical cohesion, HA also functions as a molecular trap for immune cells, notably neutrophils, through their expression of CD44. The sequestration of neutrophils within CTC clusters provides a dual advantage: protective camouflage against immune clearance and facilitation of metastatic dissemination. This immunological interplay adds another layer of complexity to the survival strategy employed by TNBC clusters during metastasis.

The translational implications of these findings are profound. By targeting the HA-CD44 axis, novel therapeutic interventions could disrupt cluster formation or induce cluster disaggregation, thereby mitigating metastatic spread. Given that similar HA-CD44 clustering mechanisms have been observed in other malignancies such as glioblastoma, prostate, and pancreatic cancers, this approach bears wide-ranging potential for combating metastasis across diverse cancer types.

This research not only elucidates a previously unappreciated role of the extracellular matrix in cancer metastasis but also redefines the paradigm of tumor cell clustering as a malleable and actively regulated process. The identification of the HA coat as a versatile mediator of cluster formation challenges existing dogma and opens new avenues for future investigation into the biophysical and biochemical determinants of cancer dissemination.

Supported by extensive NIH funding and a collaborative team of experts at Baylor College of Medicine, this advance underscores the pivotal role of interdisciplinary research integrating molecular genetics, cell biology, and clinical oncology. As the fight against metastatic cancer continues, the elucidation of HA-mediated clustering in TNBC offers a promising target for therapeutic innovation and a beacon of hope for patients afflicted with this intractable disease.

Subject of Research: Cells
Article Title: Extracellular matrix mediates circulating tumor cell clustering in triple-negative breast cancer metastasis
News Publication Date: 6-Feb-2026
Web References: https://doi.org/10.1038/s41467-026-69007-w
Keywords: Health and medicine, Clinical medicine, Diseases and disorders, Health care, Human health, Medical specialties

Triple-negative breast cancer represents a formidable challenge in oncological care, accounting for approximately 15% of breast cancer diagnoses worldwide. Characterized by the absence of estrogen receptors, progesterone receptors, and HER2 amplification, TNBC is notoriously difficult to treat, with a five-year survival rate for metastatic cases lingering near a dire 15%. The therapeutic void is exacerbated for nearly 60% of metastatic TNBC patients whose tumors do not express PD-L1, rendering immune checkpoint inhibitor therapies ineffective and narrowing treatment options significantly.

Conventional treatment modalities for TNBC have predominantly relied on chemotherapy, which, while somewhat effective, often fall short in yielding durable responses, especially among those with PD-L1-negative tumors. The urgent need for innovative, targeted therapies lagged behind scientific progress—until now. Sacituzumab govitecan, an antibody-drug conjugate (ADC), emerges as a beacon of targeted precision medicine. Its mechanism hinges on binding to Trop2, a protein abundantly expressed on the surface of TNBC cells, thereby facilitating the direct delivery of a potent cytotoxic agent to the malignancies, circumventing systemic toxicity often associated with traditional chemotherapy.

The ASCENT-03 trial, encompassing a vast cohort of 558 patients across 229 clinical sites in 30 countries, robustly evaluated the efficacy of sacituzumab govitecan as a first-line treatment against the prevailing standard chemotherapy regimens in individuals with locally advanced or unresectable TNBC lacking eligibility for immune checkpoint inhibitors. Nearly all patients—about 99%—within both study arms presented PD-L1-negative tumors, ensuring a well-defined population reflective of an unmet clinical need.

After a median follow-up period surpassing 13 months, the outcomes conveyed a compelling narrative. Patients receiving sacituzumab govitecan exhibited a median progression-free survival (PFS) of 9.7 months, notably outperforming the 6.9 months observed in the chemotherapy arm. Furthermore, patients who responded to sacituzumab govitecan treatment maintained their response for a median duration of 12.2 months, contrasting starkly with the 7.2-month median response duration among chemotherapy responders. These data underscore not only enhanced disease control but also prolonged therapeutic benefit, heralding a potentially paradigm-shifting approach in frontline TNBC management.

Although overall survival data remain in preliminary stages and require further maturation, safety analyses affirm that sacituzumab govitecan’s adverse effect profile is well-characterized, coherent with previous clinical experiences, and manageable within established guidelines employing supportive care strategies. This tolerability is pivotal, given the aggressive nature of TNBC and the critical imperative to maintain quality of life during treatment.

Experts in oncology, including Dr. Sara Tolaney from Dana-Farber Cancer Institute, highlighted the significance of these findings, emphasizing the strategic advantage of integrating more effective drugs like sacituzumab govitecan earlier in the treatment sequence. This proactive approach aims to maximize the depth and durability of tumor responses, potentially translating into improved survival outcomes and quality of life for patients historically confronted with limited options and dismal prognoses.

Sacituzumab govitecan’s journey to this milestone is rooted in foundational clinical research conducted at institutions such as Dana-Farber. Initial studies delineated the ADC’s safety and effectiveness profile, culminating in its initial U.S. FDA approval as a second-line therapy for advanced TNBC. However, clinical observations revealed that nearly half of TNBC patients do not advance to second-line treatment, underscoring the clinical imperative to shift effective interventions like sacituzumab govitecan to frontline therapy.

In addition to its application in triple-negative breast cancer, sacituzumab govitecan has demonstrated efficacy in hormone receptor-positive, HER2-negative metastatic breast cancer, as validated by the pivotal TROPiCS-02 clinical trial. This broader applicability underscores the versatility of ADC technology targeting Trop2 and presents a platform for further combinatorial strategies in breast cancer therapeutics.

Recent advancements further include data from the ASCENT-04/KEYNOTE-D19 trial evaluating the synergy between sacituzumab govitecan and pembrolizumab—an immune checkpoint inhibitor—illustrating enhanced durable responses and progression-free survival for patients with PD-L1-positive metastatic TNBC. These findings highlight a nuanced landscape where immune status biomarkers guide therapeutic combinations, tailoring approaches to tumor biology.

The ASCENT-03 trial not only elucidates a new standard of care for a challenging patient subset but also exemplifies the convergence of precision oncology, translational research, and global collaborative clinical investigation. Supported by Gilead Sciences, Inc., this endeavor advances the mission to diminish the burden of metastatic TNBC through scientifically driven, patient-centric innovation.

Dana-Farber Cancer Institute remains at the forefront of this pioneering work, distinguished as a global leader in cutting-edge oncology research and patient care. As a federally designated Comprehensive Cancer Center and an affiliate of Harvard Medical School, Dana-Farber champions a model where scientific discovery seamlessly integrates with clinical application, empowering patients through access to more than 1,200 clinical trials and novel therapies.

In summary, sacituzumab govitecan’s demonstrated superiority over standard chemotherapy in PD-L1-negative, treatment-naïve TNBC patients heralds a new era of targeted therapy in a historically refractory and aggressive cancer subtype. This breakthrough encapsulates the promise of antibody-drug conjugates to revolutionize cancer treatment paradigms by delivering cytotoxic agents directly to malignant cells while minimizing systemic exposure. Ongoing follow-up and further clinical investigation will solidify sacituzumab govitecan’s role and optimal use in the clinical armamentarium against triple-negative breast cancer.

Subject of Research: Therapeutic efficacy of sacituzumab govitecan in untreated, advanced triple-negative breast cancer patients ineligible for immune checkpoint inhibitor therapy.

Article Title: Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast Cancer

News Publication Date: October 19, 2025

Web References:

• European Society for Medical Oncology (ESMO) Congress 2025
• New England Journal of Medicine Article
• Dana-Farber Cancer Institute

References: ASCENT-03 clinical trial data; FDA approvals; TROPiCS-02 and ASCENT-04/KEYNOTE-D19 trial publications.

Keywords: Breast cancer, Triple-negative breast cancer, Sacituzumab govitecan, Antibody-drug conjugate, Progression-free survival, PD-L1 negative tumors, Targeted therapy, ADC, Chemotherapy, Immune checkpoint inhibitors.

Breast cancer stands as one of the most glaring examples of this malignant spread. The moment a primary breast tumor gives rise to metastases, the chances of survival plummet dramatically. Despite advances in medical science and treatments, tens of thousands of women continue to succumb to metastatic breast cancer each year. In light of this stark reality, the search for methods to inhibit or obliterate these perilous clusters becomes a pressing priority for oncologists and researchers alike. Recent developments in this arena indicate that there may be a glimmer of hope on the horizon.

A groundbreaking study recently published in the prestigious journal Nature Medicine unveils a novel approach to mitigating the risk of metastasis through the intervention of a familiar medication—digoxin. This compound, traditionally employed in the treatment of heart conditions, was administered in a controlled, low-dose regimen over the span of a week to nine patients diagnosed with metastatic breast cancer. The results yielded significant findings, with a pronounced average decrease of 2.2 cells per cluster among the CTCs. This reduction is remarkable given the typical size of these clusters, often comprised of merely a handful of cells. A smaller cluster size is imperative, as it correlates directly with a diminished likelihood of successful metastasis formation.

The principal investigator of the study, Nicola Aceto, who serves as a Professor of Molecular Oncology at ETH Zurich, emphasizes the critical role these CTC clusters play in breast cancer metastasis. Aceto’s findings illuminate that the efficacy of metastasis is closely tied to the size of these clusters; larger formations present a greater risk for successful metastasis. This suggests that effective strategies which can disrupt or reduce the size of these clusters may be pivotal in improving patient outcomes.

At the molecular level, it becomes apparent that the sodium-potassium pumps, or Na+/K+-ATPases, located in the membranes of tumor cells are critical to the integrity of CTC clusters. These ionic transporters are responsible for the regulation of sodium and potassium levels within the cells. By inhibiting these pumps, digoxin effectively impedes the ion exchange process. Consequently, CTCs experience an influx of calcium, leading to a weakening of the structural cohesion among cells in the clusters. As a result, the clusters have an increased tendency to disband, which could significantly thwart their metastatic potential.

However, it is vital to clarify that while digoxin shows promise in disrupting these clusters, it does not eliminate existing tumors. The findings stress that in order to achieve a comprehensive therapeutic effect, digoxin would need to be utilized in conjunction with other agents capable of directly targeting and destroying pre-existing cancer cells.

Looking ahead, the researchers are enthusiastic about optimizing the active ingredient digoxin. Its origins trace back to the plant Digitalis, commonly known as foxglove, and its medicinal utility primarily lies in treating cardiac conditions. Subsequent to the researchers’ prior discoveries in 2019, which suggested a potential role for digoxin in the context of breast cancer, a rigorous screening process was undertaken. This comprehensive evaluation explored over 2,400 different substances in cell cultures with the aim of identifying additional agents capable of combating CTC clusters.

The focus now shifts toward the development of enhanced molecules based on digoxin that can serve to more effectively dismantle these clusters, thereby enhancing the possibility of preventing metastasis. The initiative is bolstered by Page Therapeutics, a spin-off from ETH Zurich, which is actively pursuing innovative formulations that capitalize on the findings from this research.

Furthermore, Aceto’s ambitions extend beyond breast cancer; his research team intends to broaden their investigations to encompass other forms of malignancies characterized by metastatic tendencies. These include prostate, colorectal, pancreatic cancers, as well as melanoma. Initial experimental efforts to explore these avenues have already commenced within his laboratory. This ambitious expansion reflects a commitment to understanding the underlying mechanisms of metastatic progression across multiple cancer types and, ultimately, to developing targeted and effective therapeutic strategies.

This study is a commendable illustration of collaborative medical research, combining the expertise of ETH Zurich with esteemed institutions such as the University Hospitals of Basel and Zurich, along with the Basel-Land Cantonal Hospital. Such partnerships are invaluable, as hospital affiliates play an essential role in patient recruitment and the execution of clinical trials, ensuring that research findings can be translated effectively into clinical practice.

As the landscape of cancer treatment continues to evolve, the significance of finding innovative approaches cannot be overstated. The insights gleaned from this study not only contribute to the burgeoning body of knowledge surrounding metastatic breast cancer but also set the stage for future research in other cancer types. The hope is that through continued research and collaboration, effective interventions can be developed that will enhance patient outcomes and combat the pervasive threat of metastasis.

Subject of Research: Effect of digoxin on circulating tumor cell clusters in metastatic breast cancer
Article Title: Digoxin for reduction of circulating tumor cell cluster size in metastatic breast cancer: a proof-of-concept study
News Publication Date: 24-Jan-2025
Web References: DOI Link
References: Kurzeder C, Nguyen-Sträuli BD, Krol I, Ring A, et al.
Image Credits: Not specified

Keywords: Metastatic breast cancer, circulating tumor cells, digoxin, sodium-potassium pumps, cancer therapy, cancer research, tumor metastasis, oncological treatment, molecular oncology, therapeutic strategies.